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Abstract
Background and Objective Biological medicinal products
(biologics) are subject to specific pharmacovigilance
requirements to ensure that biologics are identifiable by
brand name and batch number in adverse drug reaction
(ADR) reports. Since Member States collect ADR data at
the national level before the data is aggregated at the
European Union (EU) level, it is important that an unam-
biguous understanding of which medicinal products belong
to the biological product category exists. This study aimed
to identify the level of consistency between Member States
regarding the classification of biologics by national
authorities responsible for ADR reporting.
Methods A sample list of recombinant biologics from the
European Medicines Agency database of European Public
Assessment Reports was created to analyze five Member
States (Belgium, the Netherlands, Spain, Sweden, and the
UK) according to which products were classified as bio-
logics by each Member State. We calculated the Fleiss
kappa value to analyze interrater reliability.
Results A considerable divergence was identified
regarding the classification of the 146 recombinant bio-
logics from the sample list: one Member State classified
100 % of the recombinant biologics from the sample list as
biologics, whereas the classification rates in the remaining
four Member States ranged between 70 and 88 % for
products available on the national market. The interrater
reliability for 87 products available on the market in all five
Member States was considered poor.
Conclusion Discrepancies exist between Member States
in the classification of biologics; less divergence exists for
common well-known biologics. These findings highlight
the need to think about the best approaches to translate EU
legislation into national practices. Additionally, we rec-
ommend a publicly available and frequently updated list of
centrally authorized biologics.
Key Points
The European pharmacovigilance system for
biologics requires a common understanding of which
medicinal products are classified as biologics.
Divergence exists between European Union (EU)
Member States with regard to which medicinal
products are classified as biologics and are subject to
the specific pharmacovigilance requirements for
biologics.
Provision of more accurate guidelines and support to
EU Member States could solve the issue; however,
more consideration is needed with regard to EU
regulations that depend on aligned actions of
Member States.
Electronic supplementary material The online version of this
article (doi:10.1007/s40259-015-0149-y) contains supplementary
material, which is available to authorized users.
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Biological medicinal products (biologics) are complex
medicinal products obtained from natural sources, such as
humans, animals, or microorganisms. Biologics differ from
other medicines by the use of living cells, the complexity
of the manufacturing process, and the highly complex
structures of the biological products [1, 2]. A subset of
biologics is the recombinant biologics, which are produced
by genetic engineering techniques [3]. In 1982, the first
recombinant biologic, a human insulin produced in
Escherichia coli, was introduced on the European Union
(EU) market under the brand name Humulin [4]. Since
then, more than 100 recombinant biologics have been
introduced, with the number of new market authorizations
still increasing each year.
Biologics are sensitive to changes in the manufacturing
process: small alterations—for example, to improve pro-
duct properties or product yield—may influence the safety
characteristics of the biological product and can result in
batch-to-batch variations [5, 6]. For this reason, biologics
are subject to specific regulations and guidelines. In the
EU, for example:
• To reduce product-to-product variations, the regulatory
approval pathway for follow-on biological medicinal
products (biosimilars) differs from the approval path-
way for small-molecule follow-on products (generics).
For biosimilars, clinical data are required to demon-
strate their similarity in terms of quality, safety, and
efficacy [7].
• To reduce batch-to-batch variations, biologics undergo
much stricter manufacturing requirements than small-
molecule medicines, thus minimizing the chance of
product variations during the life cycle of the biologic
[8, 9].
In light of the above, the pharmacovigilance require-
ments in place for biologics in the EU differ from those for
small molecules. The Pharmacovigilance Directive
(Directive 2001/83/EC) dictates that all EU Member States
shall ensure that a biological medicinal product that is the
subject of a suspected adverse drug reaction (ADR) report
is identified by the (brand) name of the medicinal product
and the batch number [10].
Since Member States collect ADR data at the national
level, a consistent and uniform approach to pharmaco-
vigilance activities is needed in order to maintain European
alignment. For biologics, this consistent and uniform
approach starts with an unambiguous understanding of
which medicinal products belong to the biological product
category. However, no comprehensive list of approved bio-
logics in the EU is readily available from an authoritative
source (e.g. the European Medicines Agency [EMA] web-
site). This could possibly lead to divergence between
Member States on what is regarded as a biologic at the
national level. The aim of this study was therefore to identify
the level of consistency between EU Member States with
regard to the classification of biologics by the authorities
responsible for ADR reporting at the national level.
2 Methods
2.1 Products Included in the Analysis
Since no predefined list of approved biologics in the EU is
readily available, we had to define the scope of our anal-
yses first. For the purpose of this study, we decided to focus
on recombinant biologics because clear definitions are
available for this subset of biologics [11]. A sample list of
recombinant biologics was created in two steps, based on
the EMA database of European Public Assessment Reports
(EPARs) of centrally approved medicinal products. As a
first step, we screened the title of Annex II-A of the pro-
duct information in the EPAR to select a group of candi-
date biologics. If the title contained the text
‘‘Manufacturers of the biological active substance…’’ we
assumed the product was a biologic. As a second step, to
select recombinant biologics, we screened Section 2 of the
Summary of Product Characteristics (SmPC) ‘‘Qualitative
and quantitative composition’’ chapter to assess whether it
mentioned recombinant manufacturing techniques. The
criteria for inclusion on our sample list were the men-
tioning of recombinant DNA (rDNA) manufacturing
methods and/or the naming of the cell line used in the
manufacturing process. Seven recombinant biologics (four
somatropins, one epoetin alfa, one insulin human, and one
filgrastim) were added to the list because they were
approved prior to 1995 (before the EMA started its activ-
ities) and are still commonly used in clinical practice.
Recombinant vaccines were excluded because vaccines are
subject to specific pharmacovigilance practices. The sam-
ple list of recombinant biologics was categorized into 11
product classes based on the international nonproprietary
names (INNs) and/or anatomical therapeutic chemical
(ATC) classifications. We used an extraction of medicinal
products from the EMA database on 30 November 2014.
The full list can be found in Table S1 in the Electronic
Supplementary Material.
2.2 Member States Included in the Analysis
We selected five different national pharmacovigilance
centers from EU Member States that take specific measures
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to allow the reporter of an ADR (e.g. a physician, patient,
or pharmacist) to ascertain that the suspected medicinal
product is a biologic: Federaal Agentschap voor
Geneesmiddelen en Gezondheidsproducten (FAGG), Bel-
gium; Netherlands Pharmacovigilance Centre Lareb, the
Netherlands; Agencia Espan˜ola de Medicamentos y Pro-
ductos Sanitarios (AEMPS), Spain; Medical Products
Agency (MPA), Sweden; and Medicines and Healthcare
Products Regulatory Agency (MHRA) Yellow Card
Scheme, UK. This ascertainment can be done actively, by
notifying the reporter in the online ADR reporting form
that the submitted medicinal product is a biologic (through
a pop-up feature asking the reporter to provide the batch
number), or passively by maintaining a list of biologics on
the website, which can be consulted by the reporter. Of the
selected Member States, the Netherlands and the UK have
implemented an active notification feature; the national
pharmacovigilance centers in Belgium, Spain, and Sweden
maintain a list of biologics on their website [12–14]. For
the purpose of this study, we did not distinguish between
active and passive notification features, since both notifi-
cation features serve the same purpose and were equally
suitable for our analysis.
2.3 Analysis of Biologic Classifications in Member
States
We assessed which of the products on our sample list of
recombinant biologics were classified as biologics in the
five selected Member States according to the active or
passive methods described above. We limited our analysis
to recombinant biologics that were marketed in the
respective Member States. To determine which biologics
were available on the market in the Netherlands, the UK,
and Spain, we assumed that the ability to report a biologic
in their respective online ADR reporting forms is an indi-
cator of their availability.1 For Belgium and Sweden, a list
of medicinal products available on the national market was
consulted [15, 16]. All analyses were conducted on the
basis of the situation on 19 February 2015.
Results were reported as the proportions of biologics
from our sample list of recombinant products that were
classified as biologics in each Member State. Subanalyses
for specific individual biologics and product classes were
conducted. We calculated the Fleiss kappa value to assess
interrater reliability regarding the classification of the
recombinant biologics from our sample list that were
available on the market in all five Member States [17]. We
anonymized the Member States in this analysis, since the
objective of this study was to highlight the diversity in the
classification of biologics in different Member States,
rather than to judge individual Member States.
3 Results
Table 1 shows that one Member State (State E) has clas-
sified 100 % of the recombinant biologics that are on our
sample list and are available on their national market as
biologics, whereas the remaining Member States (Sta-
tes A–D) have classified between 70 and 88 % on this
metric. In addition, State E is the only Member State that
has all recombinant biologics from the sample list available
on its national market.
During the comparison of different product classes, it
was observed that the somatropins are the only product
class classified as biologics by all Member States. In con-
trast to the somatropins, the percentages of the follitropins
classified as biologics vary from 0 to 100 %. For the
recombinant biologics that do not belong to a distinct
product class (other), the percentages of the recombinant
biologics from our sample list that are classified as bio-
logics vary between 31 and 81 % for the Member States,
with the exception of State E (classification rate 100 %).
An assessment of individual product classes reveals that
class-specific differences between Member States exist. For
example, State A has classified 92 % of the 13 nationally
available insulins as biologics, whereas State B has classi-
fied 30 % of the 10 insulins available on its market as bio-
logics. However, of the 33 monoclonal antibodies available
in State A, 45 % have been classified as biologics, whereas
State B has classified 92 % of the 26 monoclonal antibodies
available on its national market as biologics.
Of the 146 recombinant biologics on our sample list, 87
were available on the national markets of all five Member
States. Fifty-one (59 %) of these 87 recombinant biologics
were classified as biologics by all five Member States. Of
the remaining 36 recombinant biologics, 25 were classified
as biologics by four Member States, seven by three
Member States, and four by two Member States (Table 2).
The Fleiss kappa value for these 87 recombinant biologics
is 0.0782. We interpret this as poor agreement among the
Member States regarding the classification of these 87
recombinant biologics that are marketed in all five Member
States [18].
4 Discussion
The results of this study show that there is considerable
divergence between a selected group of EU Member States
with regard to which medicinal products are classified as
1 The online reporting forms in the Netherlands, the UK, and Spain
consist of an autocomplete function, which allows identification of the
medicinal products available in the national reporting form.
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biologics in their national pharmacovigilance systems. For
this topic, it is particularly relevant that national pharma-
covigilance practices should be aligned with the EU
pharmacovigilance requirements, in order to facilitate
timely and accurate ADR signal detection [19]. It seems
that less divergence exists for common well-known bio-
logics. For example, of the 51 recombinant biologics from
our sample list that are classified as biologics by all five
Member States, 31 (61 %) were listed among the top 50
best-selling biologics in the EU and the USA in 2010 [20].
Of the 11 recombinant biologics that were classified as
biologics by only two or three Member States, seven
(64 %) had been approved by the EMA since 2009.
Besides potential limited familiarity with recently intro-
duced recombinant biologics, another reason for this find-
ing could be lack of frequent updates of the national
product lists and databases. Three of the four recombinant
biologics (75 %) that were classified as biologics by only
two Member States are orphan medicines, which may
support the hypothesis that biologics rarely used in clinical
practice are less likely to be classified as biologics in
pharmacovigilance systems.
There are certain limitations that apply to this study.
First, we were able to include only a limited number of EU
Member States in our analysis, which may have introduced
bias and influenced our findings. We also examined
national pharmacovigilance centers in other Member States
by directly accessing their (online) ADR reporting forms
and/or by approaching the national pharmacovigilance
centers by e-mail to ask if specific measures have been
taken. The majority of the national pharmacovigilance
centers did not have an active or passive notification
feature, or they were not directly accessible (e.g. because
of the requirement for a national ID for access, error
messages, or translation issues) and therefore were not
included in the analysis. When contacted, several Member
States responded that currently there is no comprehensive
and centrally obtainable list of all approved biologics
available in the EU. The five Member States that were
included in this analysis have a long tradition in the field of
pharmacovigilance and have been part of the EU regulated
space since the launch of the EMA. We therefore expect
that the divergence might even increase with more Member
States being included in the analysis.
Second, we assumed that the ability to report a recom-
binant biologic via the online ADR reporting form indi-
cates its availability. However, we do not know exactly
how national drug lists are created and how they are linked
to online ADR reporting forms. Although we made this
assumption, we believe this provided a reasonable esti-
mation of the recombinant biologics available on the
market and appropriate to be considered for the analysis in
individual Member States.
Third, there may be a time lag between the introduction
of a recombinant biologic to the EU market and its clas-
sification as a biologic in the national reporting system of
each Member State. We did not explore that possibility in
this study. However, the discrepancies we identified were
not limited to recombinant biologics recently introduced to
the EU market.
Fourth, the sample list of recombinant biologics that we
created for this study may not have been complete. Since
this was a manual exercise, we might have overlooked
some recombinant biologics in the EMA database. This
Table 1 Overview of the percentages and numbers of marketed recombinant biologics classified as biologics in each Member State’s national
pharmacovigilance system
Product class Na Classification of marketed biologics as biologics [% (n)]b
Member State A Member State B Member State C Member State D Member State E
Somatropins 7 100 (6) 100 (6) 100 (5) 100 (5) 100 (7)
Epoetins 11 100 (7) 88 (8) 100 (6) 100 (7) 100 (11)
Filgrastims 11 83 (6) 100 (8) 67 (6) 88 (8) 100 (11)
Follitropins 7 60 (5) 0 (4) 75 (4) 86 (7) 100 (7)
Monoclonal antibodies 35 45 (33) 92 (26) 89 (28) 74 (35) 100 (35)
Insulins 19 92 (13) 30 (10) 100 (10) 100 (13) 100 (19)
Interferons 9 100 (6) 100 (8) 86 (7) 89 (9) 100 (9)
Antihemophilic factors 8 86 (7) 100 (6) 100 (6) 88 (8) 100 (8)
Fusion proteins 5 40 (5) 67 (3) 75 (4) 80 (5) 100 (5)
Enzymes 13 91 (11) 58 (12) 91 (11) 91 (11) 100 (13)
Other 21 53 (17) 31 (16) 75 (12) 81 (21) 100 (21)
Total 146 70 (116) 71 (107) 88 (99) 85 (129) 100 (146)
a N is the number of recombinant biologics on our sample list
b n is the number of recombinant biologics available on the national market
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Table 2 Overview of the 87 recombinant biologics marketed in all Members States and the numbers of Member States classifying each one as a
biologic in their national pharmacovigilance systems, sorted by product class









Somatropins Somatropin (n = 5)b
Epoetins Darbepoetin alfa Methoxy polyethylene glycol-epoetin beta




Filgrastim (n = 3)b
Follitropins Follitropin alfa Corifollitropin alfa Follitropin alfa/lutropin alfa
Follitropin beta
Monoclonal antibodies Bevacizumab Certolizumab pegol Belimumab Brentuximab vedotin
Cetuximab Canakinumab Ipilimumab
















Insulin aspart (n = 2)b
Interferons Interferon alfa-2b




Antihemophilic factors Eptacog alfa (activated)










Other Palifermin Thyrotropin alfa Teriparatide Mecasermin
Choriogonadotropin alfa Dibotermin alfa Lutropin alfa Romiplostim
Pegvisomant Liraglutide
a N is the total number of marketed biologics classified as biologics by the specified number of Member States
b n is the number of recombinant biologics that share the same international nonproprietary name (INN) and are classified by the specified number of
Member States
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could have skewed the percentages of classification of
biologics in the results, although presumably in a limited
fashion and most likely nondifferential to the outcome.
Furthermore, we included only recombinant biologics in
our analysis, although this topic concerns biologics in
general.
In the end, the purpose of this study was to assess the
level of consistency between EU Member States with
regard to which medicinal products are classified as bio-
logics in national pharmacovigilance systems. As stated
earlier, our aim was not to take a judgmental view on the
appropriateness of the classification of biologics in Mem-
ber States but to highlight an issue in the area of the
pharmacovigilance of biologics that is relevant from an EU
perspective. For the topic at hand, a feasible solution would
be a publicly available and frequently updated list of
centrally authorized biologics. This would help to improve
the EU pharmacovigilance system by facilitating alignment
of EU Member States in the classification of biologics.
From a broader perspective, these findings also highlight
the need to think about the best approaches to translate EU
legislation into national practices. As seen in the results,
discrepancies between Member States are especially criti-
cal for EU-wide regulatory approaches, which call for
harmonization of national regulatory requirements and
practices.
5 Conclusion
The pharmacovigilance system in the EU requires a har-
monized method of classification of biologics in order to
make aggregated data sets, such as Eudravigilance, of the
highest value [21]. As this study shows, there are consid-
erable discrepancies between Members States in the clas-
sification of which medicinal products are biologics, which
may influence the quality and quantity of the available
aggregated data and hence may hamper tailored pharma-
covigilance for biologics. Although this divergence can be
(and should be) easily resolved, we would like to encour-
age policy makers to consider how we can make sure that
EU regulation in the area of medicines, which depends on
aligned actions by Member States to achieve public health
objectives, leads to practices that are able to fulfil all of the
requirements of such regulations in an appropriate, prag-
matic, and feasible manner.
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